期刊
CURRENT DIABETES REPORTS
卷 16, 期 3, 页码 -出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-016-0727-5
关键词
Diabetic neuropathy; Peripheral nerve dysfunction; Chronic inflammation; Inflammatory cytokines
资金
- National Institutes of Health [1R01HL102334, 1R03 DK094499, 1DP3DK094292, 1R24082841]
- Novo Nordisk Foundation [NNF14SA0006]
- Program for Neurology Research and Discovery
- A. Alfred Taubman Medical Research Institute
Diabetic neuropathies (DNs) are one of the most prevalent chronic complications of diabetes and a major cause of disability, high mortality, and poor quality of life. Given the complex anatomy of the peripheral nervous system and types of fiber dysfunction, DNs have a wide spectrum of clinical manifestations. The treatment of DNs continues to be challenging, likely due to the complex pathogenesis that involves an array of systemic and cellular imbalances in glucose and lipids metabolism. These lead to the activation of various biochemical pathways, including increased oxidative/nitrosative stress, activation of the polyol and protein kinase C pathways, activation of polyADP ribosylation, and activation of genes involved in neuronal damage, cyclooxygenase-2 activation, endothelial dysfunction, altered Na+/K+-ATPase pump function, impaired C-peptide-related signaling pathways, endoplasmic reticulum stress, and low-grade inflammation. This review summarizes current evidence regarding the role of low-grade inflammation as a potential therapeutic target for DNs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据